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We previously described a thymus-tropic HIV-1 envelope (R3A Env) from a rapid progressor obtained at the time of transmission. An
HIV-1 molecular recombinant with the R3A Env supported extensive replication and pathogenesis in the thymus and did not require Nef.
Another Env from the same patient did not display the same thymus-tropic pathogenesis (R3B Env). Here, we show that relative to R3B Env,
R3A Env enhances viral entry of T cells, increases fusion-induced cytopathicity, and shows elevated binding efficiency for both CD4 and
CXCR4, but not CCR5, in vitro. We created chimeric envelopes to determine the region(s) responsible for each in vitro phenotype and for
thymic pathogenesis. Surprisingly, while V1/V2 contributed to enhanced viral entry, CD4 binding efficiency, and cytopathicity in vitro, it
made no contribution to thymic pathogenesis. Rather, CXCR4 binding efficiency and V5-gp41-associated activity appear to independently
contribute to thymic pathogenesis of the R3A Env. These data highlight the contribution of unique HIV pathogenic factors in the thymic
microenvironment and suggest that novel mechanisms may be involved in Env pathogenic activity in vivo.
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Disease progression in HIV-1-infected individuals is
influenced by both the virus and the immune system.
Progressive disease results in eventual depletion of CD4+ T
cells and the onset of AIDS (McCune, 2001). During
progression, variants often emerge with Env proteins
capable of using CXCR4 as a coreceptor in addition to or
instead of CCR5 (Koot et al., 1993; Tersmette et al., 1989).
The emergence of CXCR4-tropic Env proteins has been
associated with disease progression, loss of T cell homeo-
stasis, and the onset of AIDS (Connor et al., 1993; Koot
et al., 1993; Margolick et al., 1995; McCune, 2001;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: lsu@med.unc.edu (L. Su).Philpott, 2003; Richman and Bozzette, 1994). In addition
to coreceptor usage, affinity for coreceptor (Chakrabarti
et al., 2002; Etemad-Moghadam et al., 2000; Gorry et al.,
2002; Karlsson et al., 1998, 2004; Si et al., 2004),
enhanced fusion in vitro (Chakrabarti et al., 2002;
Etemad-Moghadam et al., 2001; Karlsson et al., 1998),
enhanced syncytium-induction in vitro (Etemad-Mogha-
dam et al., 2001; Karlsson et al., 1998; Rudensey et al.,
1998), and enhanced resistance to neutralizing antibodies
(Etemad-Moghadam et al., 1999; Richman et al., 2003;
Rudensey et al., 1998; Wei et al., 2003) have all been
correlated with viral pathogenesis and disease progres-
sion. However, mechanistic details of Env-mediated
pathogenesis in vivo and their relationship to disease
progression remain to be fully explained.
Many of the insights into mechanisms of viral patho-
genesis have been derived from simian studies which allow
for experimental manipulation and testing of hypotheses in05) 184 – 197YVIRO-03031; No. of pages:14; 4C: 5
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in humans must largely be drawn by correlation. Model
systems to study pathogenesis of HIV-1 include immortal-
ized cell lines, artificially stimulated primary cells, and the
more relevant SCID-hu thy/liv and human fetal-thymus
organ culture (HF-TOC) models. These thymus models
contain primary cells that limit replication of tissue culture-
adapted isolates but which support replication and patho-
genesis of primary isolates without exogenous stimulation
(Meissner et al., 2003; Miller et al., 2001). These models
can be used not only to study the effect of HIV-1 on the
thymus, but also as general models of lymphoid micro-
environments that HIV-1 encounters in vivo.
We previously characterized two env genes (R3A and
R3B) isolated at the time of transmission from a patient who
progressed rapidly to AIDS (Meissner et al., 2004). While
both Env proteins support infection and depletion of
stimulated PBMCs, the R3A Env enables elevated repli-
cation and pathogenesis in the thymus, even in the absence
of Nef. In this report, we demonstrate that the R3A Env
displays enhanced virus-cell fusion, fusion-induced cytopa-
thicity, and CXCR4 binding efficiency relative to the R3B
Env in a panel of in vitro assays. Furthermore, R3A Env
shows enhanced sensitivity to inhibition by soluble CD4
and elevated resistance to Leu3a, a CD4 blocking antibody,
suggesting that it has higher affinity for CD4 relative to R3B
Env. Using recombinant env genes which allowed for
mapping of each phenotype, we dissect the contribution of
putative mechanisms to thymic replication and pathogene-
sis. Surprisingly, elevated CD4 binding efficiency and
enhanced viral-cell fusion, both mediated by the V1/V2
region, do not determine thymic replication and patho-
genesis. Rather, the data suggest a contribution of CXCR4
binding efficiency and the V5-gp41 region of Env. These
data highlight the separation that can exist between in vitro
correlates of pathogenesis and factors relevant within a
model lymphoid microenvironment.Fig. 1. The R3A Env mediates elevated viral fusion with CD4+ T cells.
Blam-vpr-containing virions were used to infect Sup-T1 cells by
spinoculation. After 2 h of incubation at 37 -C, cells were incubated with
flurogenic beta-lactamase substrate for 8 h. The amount of entry was
calculated by measuring the ratio of cleaved to uncleaved flurogenic
substrate. Shown is a representative of eight independent experiments with
error bars derived from triplicate samples and input virus determined by
p24 ELISA. (*P <0.05 for R3A vs. either NL4-3 or R3B).Results
The R3A Env enables enhanced viral entry of T cells
The R3A Env was previously shown to mediate high
levels of replication and pathogenesis in the thymus relative
to the R3B or NL4-3 envelopes, either in the context of the
parental virus or in a recombinant virus lacking Nef (NL4-
R3A and NL4-R3B). We previously showed that NL4-luc
pseudotyped with R3A Env has increased infectivity for
Sup-T1 cells in a single cycle replication assay, which could
help explain enhanced thymic replication (Meissner et al.,
2004). To extend this finding, we employed the Blam-vpr
assay to determine if increased infectivity was correlated
with increased viral entry of T cells (Cavrois et al., 2002;
Lineberger et al., 2002). When beta-lactamase-expressing
virions were used to infect Sup-T1 cells, we found thatNL4-R3A was significantly more capable of entering cells
than either NL4-R3B or NL4-3 for a given amount of p24
(Fig. 1). Similarly, we found that the R3A Env expressed on
A293T cells was more fusogenic towards 1G5 cells in a
cell–cell fusion assay (data not shown). Notably, incorpo-
ration of R3A and R3B Env into virions and surface
expression of each Env on A293T cells were comparable
(data not shown).
The R3A Env has higher binding efficiency for CD4
Fusion efficiency is determined by interaction of Env
with CD4, CCR5 and/or CXCR4, and the nature of the
fusion intermediate (Doms, 2000; Eckert and Kim, 2001;
Wyatt and Sodroski, 1998). To test which interaction might
explain the enhanced entry mediated by the R3A Env, we
infected cell lines in the presence of chemical inhibitors to
each of these four components. We first tested relative
binding efficiency for CD4 by assessing sensitivity of
pseudotyped virus to inhibition by soluble CD4 (sCD4)
(Beaumont et al., 2004; Kozak et al., 1997; Thali et al.,
1991). Because the infectivity of each virus differs
(Meissner et al., 2004 and Fig. 1), we normalized infection
achieved in the presence of sCD4 to that achieved with no
sCD4 for each virus. NL4-3 was found to have the greatest
sensitivity to sCD4 (Fig. 2A), consistent with previous
findings that tissue culture-adapted viruses typically have
increased binding efficiency for CD4 relative to primary
envelopes (Kozak et al., 1997; Moore et al., 1992; Platt
et al., 2000). Notably, R3A-pseudotyped virus was more
sensitive to sCD4 inhibition than R3B-pseudotyped virus,
suggesting that R3A has increased binding efficiency for
CD4.
To extend these findings, and because other mecha-
nisms may be involved in sCD4 sensitivity, we infected
Sup-T1 cells in the presence of Leu3a, an anti-CD4
Fig. 2. The R3A Env shows enhanced sensitivity to sCD4 and reduced sensitivity to Leu3a. (A) R3A Env is sensitive to sCD4 relative to R3B Env. TZM-bl
cells were infected with virus incubated with sCD4 for 2 h prior to infection. Infection was quantitated by luciferase assay 48 h post-infection and values were
normalized to infection in the absence of sCD4. Shown is a representative of 3 experiments with error bars derived from duplicate samples. (B) R3A Env is
resistant to Leu-3a relative to R3B Env. Sup-T1 cells were preincubated with the indicated dose of Leu-3a for 1 h prior to infection with pseudotyped NL4-luc.
Infection achieved by spinoculation was quantitated by luciferase assay 48 h post-infection and values were normalized to infection in the absence of Leu-3a.
Shown is a representative of 3 experiments with error bars derived from quadruplicate samples (*P <0.05 for R3B vs. either NL4-3 or R3A).
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binding to CD4. R3B-pseudotyped virus was found to be
significantly more sensitive to inhibition by Leu3a than
either NL4-3 or R3A Env (Fig. 2B). Together, these data
suggest that R3A Env has higher binding efficiency for
CD4 than R3B Env.
The R3A Env has higher binding efficiency for CXCR4 than
the R3B Env, but similar CCR5 binding efficiency and
sensitivity to T20
When U373-MAGI-CCR5E cells were infected in the
presence of the CCR5 antagonist Tak-779 (Baba et al.,
1999; Este, 2001), NL4-R3B and NL4-R3A were found to
have similar sensitivity to inhibition, suggesting they have
similar binding efficiency for CCR5 (Fig. 3A) (Gorry et al.,
2002). In contrast, when Sup-T1 cells were infected with
pseudotyped virus in the presence of the CXCR4 antagonist
AMD-3100, R3A-pseudotyped virions were markedly less
inhibited than either R3B- or NL4-3-pseudotyped virions
(Fig. 3B). A similar increase in resistance to AMD-3100
was observed for R3A Env when GHOST-CXCR4 cells
were used for infection (data not shown). Additionally,
infection of CXCR4-shRNA-expressing Sup-T1 cells,
which express ¨3% of control CXCR4, was much more
efficient with R3A Env (Fig. 3C). These data suggest that
R3A Env has higher binding efficiency for CXCR4 than
R3B Env.
Because coreceptor affinity has been correlated with
resolution of the fusion intermediate and sensitivity to
fusion inhibitors (Reeves et al., 2002), we tested the relative
sensitivity of each virus to inhibition by the fusion inhibitor
T20. As shown in Fig. 3D, NL4-3, NL4-R3B, and NL4-
R3A had equal sensitivity to T20. We conclude that R3A
Env has enhanced binding efficiency for both CD4 and
CXCR4, but not CCR5, relative to R3B Env, and thisincrease in binding efficiency does not manifest in differ-
ential sensitivity to T20. Furthermore, NL4-R3B and NL4-
R3A were found to incorporate similar levels of envelope
and were equally sensitive to heat denaturation (data not
shown), suggesting increased CD4 and CXCR4 affinities
are intrinsic properties of the R3A Env.
The R3A Env induces syncytium formation and
fusion-induced cytopathicity when expressed in T cell lines
We previously showed that expression of R3A on
A293T cells leads to increased depletion of CD4+
thymocytes in a coculture assay (Meissner et al., 2004),
which could correlate with thymic replication or patho-
genesis. To extend these findings, we assessed whether the
R3A Env is cytopathic when expressed in T cells in vitro.
Retrovirus vector expressing the Env gene was used to
transduce either 1G5 or Sup-T1 cells. Each vector also
expresses GFP controlled by the phospho-glucose kinase
promoter (Coffield et al., 2003, 2004), allowing for
transduction efficiency to be monitored by FACS analysis
of GFP expression. At 72 h post-transduction, both 1G5
(Fig. 4A) and Sup-T1 cells (data not shown) showed
equivalent transduction efficiencies, with over 90% of cells
routinely expressing GFP. Furthermore, the amount of Env
expressed in each cell population, as assessed using the
anti-gp120 2G12 monoclonal antibody, was comparable
across samples in 1G5 cells (Fig. 4A). Similar but lower
levels of Env were detected on transduced Sup-T1 cells
(data not shown).
Observation of cells 3 days post-transduction showed
the R3A Env induced extensive syncytia formation to an
extent not observed in vector, NL4-3 Env, or R3B Env-
expressing cells (Fig. 4B). Smaller syncytia and clumping
were consistently observed in R3B-expressing cells, but
never to the extent seen in R3A-expressing cells. To
Fig. 3. The R3A Env shows enhanced binding efficiency for CXCR4, but similar sensitivity to Tak-779 and T20. (A) R3A and R3B Envs show equal
sensitivity to a CCR5 antagonist. Infection of U373-MAGI-CCR5E cells was performed in the presence of the CCR5 antagonist TAK-779. Infection was
quantitated by counting blue colonies and was normalized to the number of colonies observed with no TAK-779. Shown is a representative of two independent
experiments with error bars derived from quadruplicate samples. (B) R3A shows enhanced affinity for CXCR4 relative to R3B. Infection of Sup-T1 cells was
performed with NL4-luc-pseudotyped virus in the presence of AMD-3100. Infection was quantitated by luciferase assay after 48 h and was normalized to levels
obtained with no AMD-3100. Shown is a representative of seven independent experiments with error bars derived from triplicate samples (*P <0.05 for R3A
vs. either NL4-3 or R3B). (C) Sup-T1 cells transduced with vector or X4h shRNA, which reduces CXCR4 surface levels by¨97%, were infected with NL4-luc
pseudotyped with the indicated Env. Infection was quantitated by luciferase assay after 48 h and was normalized to levels obtained on vector-transduced cells.
Shown is a representative of three independent experiments with error bars derived from triplicate samples (*P <0.05 in comparison to R3A Env or to infection
of parental cells). (D) R3A and R3B Envs show equal sensitivity to the fusion inhibitor T20. TZM-bl cells were infected with virus in the presence of the
indicated dose of T20. Infection was quantitated and normalized as in A. Shown is a representative of 2 experiments with error bars derived from duplicate
samples (*P <0.05 for NL4-R3A vs. either NL4-3 or NL4-R3B).
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living cells surviving 3 days post-transduction was
quantitated by trypan blue exclusion. In both 1G5 and
Sup-T1 cells, R3A Env was significantly more cytopathic
than either NL4-3 or R3B Env (Fig. 4C and data not
shown).
R3A-expressing Sup-T1 cells were next cultured in the
presence of either T20 or AMD-3100, inhibitors of
envelope fusion and CXCR4 interactions. Both drugs
significantly ablated R3A Env-induced cytopathicity (Figs.
4D–E), indicating that cytopathicity in this system is
dependent on fusion of envelope with target cells and is
not simply a byproduct of intracellular envelope toxicity.
Collectively, these data indicate that the R3A Env
expressed from T cells is more cytopathic per Env
molecule than NL4-3 or R3B Env, suggesting that R3A
Env may be intrinsically more cytopathic when expressed
on infected thymocytes.Enhanced entry and CD4 binding efficiency of the R3A Env
map to the V1/V2 region, while CXCR4 binding efficiency is
due to multiple determinants
We previously determined that the R3A and R3B Env
proteins show a high degree of sequence homology. The
vast majority of sequence variation is in the variable
regions, with scattered differences in the gp41 ecto- and
intracellular domains (Meissner et al., 2004 and Fig. 5). In
an attempt to delineate the regions responsible for the
phenotypes observed above, we constructed chimeric
envelopes using conserved restriction sites. Eight chimeric
envelopes were made by switching the pre-V1, V1/V2, V4,
or the V5-gp41 regions between R3A and R3B (Fig. 5).
Four of the recombinant env genes were introduced into the
NL4-3 backbone (V1/V2 and V5-gp41 recombinants)
which, like NL4-R3A and NL4-R3B, resulted in deletion
of the nef gene (Meissner et al., 2004). Notably, while the
E.G. Meissner et al. / Virology 336 (2005) 184–197188
Fig. 5. Generation of recombinant env genes to map the pathogenic determinants in the R3A Env. Schematic map of the eight recombinant env genes made
using conserved restriction sites. Vertical bars indicate specific amino acid differences between R3A and R3B Env proteins. The total number of differences in
each region of Env is indicated. The asterisk indicates the additional putative glycosylation site in the R3B Env.
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R3A and R3B have identical V3 loops and thus V3 is not
included in the recombinant notation. We tested each of the
eight chimeric Env proteins and the four recombinant
viruses in the in vitro assays that best distinguish the R3A
and R3B Env proteins.
The recombinant viruses were first tested in the Blam-vpr
assay to determine the Env region responsible for enhanced
viral entry of T cells. As shown in Fig. 6A, switching the
V1/V2 region caused an almost complete switch in
phenotype, with the R3B (R3A V1/V2) Env showing
greater entry than the R3A (R3B V1/V2) Env. In contrast,
switching the V5-gp41 region caused little change in entry.
Similar results were obtained in an A293T-Env/1G5 cell–
cell fusion assay (data not shown). We conclude that the V1/
V2 region is the predominant mediator of increased entry
for the R3A Env.
We next tested the binding efficiency of each chimeric
Env for CD4 and CXCR4. As shown in Fig. 6B, the V1/V2
region was the predominant mediator of sensitivity to sCD4,
with a complete switch in phenotype between R3B (R3A
V1/V2) and R3A (R3B V1/V2). In contrast, the pre-V1, V4,
and V5-gp41 regions did not contribute greatly to sCD4
sensitivity. When each of the chimeric Envs was tested for
CXCR4 binding efficiency, we were unable to detect the
contribution of a distinct region (Fig. 6C). Instead, each
R3B recombinant with a single R3A region was still low in
resistance and each R3A recombinant with a single R3BFig. 4. The R3A Env causes cytopathicity through CXCR4-dependent fusion when
expressing HIV Env. Env surface levels were detected 3 days post-transduction u
Shown is a representative stain 3 days post-transduction. The percentage of cel
formation. Syncytia were observed by light microscopy 3 days post-transduction.
(C) The number of live cells surviving 3 days post-transduction was quantitate
experiments for Sup-T1 cells. (D and E) R3A-induced cytopathicity is dependen
incubated with no drug, with T20 (D), or with AMD-3100 (E), and cytopathic
experiments (*P <0.05 for R3A and R3B vs. vector transduced cells).region was still high in resistance, suggesting that multiple
regions of the R3A Env are responsible for increased
CXCR4 binding efficiency. Together, these data suggest that
enhanced viral entry mediated by the R3A Env is due to its
unique V1/V2 loop which, in turn, determines binding
efficiency for the CD4 receptor. Furthermore, based on
mapping data, there appears to be no linkage between viral
entry and CXCR4 binding efficiency, suggesting that
coreceptor engagement is not the limiting step for viral
entry.
V1/V2 and V5-gp41 independently contribute to
fusion-induced cytopathicity
Each chimeric Env was next tested for fusion-induced
cytopathicity in Sup-T1 cells. As above, the R3A Env was
more cytopathic to T cells than NL4-3 or R3B Env (Fig. 7).
The pre-V1 and V4 regions were not found to contribute to
cytopathicity by either syncytia size or cytopathicity quanti-
tation. In contrast, swapping the V1/V2 regions between the
Env proteins resulted in the formation of syncytia of
intermediate size, while expression of R3B (R3AV5-gp41)
caused syncytia that appeared larger than cells expressing
R3A (R3B V5-gp41) (data not shown). Quantitation of
cytopathicity by live cell counting confirmed an independent
contribution of both V1/V2 and V5-gp41 to cytopathicity,
with a slightly more impressive contribution of the V5-gp41
region (Fig. 7). These data suggest the contribution of twoexpressed in T cells. (A) 1G5 cells were transduced with a retroviral vector
sing the 2G12 monoclonal antibody or human IgG1 as an isotype control.
ls in each quadrant is indicated. (B) R3A Env induces extensive syncytia
Shown are representative photos of Sup-T1 cells 3 days post-transduction.
d by trypan blue exclusion. Shown is a representative of 8 independent
t on fusion through CXCR4. Vector or R3A-transduced Sup-T1 cells were
ity was quantitated as in C. Shown is a representative of 2 independent
Fig. 6. The V1/V2 region is largely responsible for the enhanced entry and CD4 affinity of R3A Env, while CXCR4 affinity cannot be mapped to one particular
region. (A) V1/V2 contributes to enhanced virus fusion of T cells. Blam-vpr-containing virions were used to infect Sup-T1 cells at the dose of p24 indicated.
Shown is a representative of 5 independent experiments with error bars derived from quadruplicate samples (*P <0.05 for the indicated recombinant relative to
the parental envelope at the highest two doses of p24). (B) Soluble CD4 sensitivity also maps to the V1/V2 region. NL4-luc-pseudotyped virus was pretreated
with 4 Ag/ml sCD4 prior to infection of GHOST-CXCR4 cells. Infection in the presence of sCD4 was compared to infection without sCD4 treatment. Shown is
a representative of 2 experiments with error bars derived from quadruplicate samples. (C) Resistance to AMD-3100 is achieved by multiple determinants. Sup-
T1 cells were infected with pseudotyped NL4-luc in the presence of 200 nM AMD-3100. Resistance to inhibition observed with the R3A Env was assigned a
value of 1 for each of four experiments, and the relative resistance of each recombinant Env was normalized to this value. Shown are the combined results from
four independent experiments with standard error bars indicated.
Fig. 7. V1/V2 and V5-gp41 independently contribute to enhanced fusion-
induced cytopathicity of R3A Env. Sup-T1 cells were transduced with Env
expression vectors. Cytopathicity was quantitated as in Fig. 2. *Signifi-
cantly different from the parental envelope, **significantly different from
both R3A and R3B Env ( P <0.05). Shown are the combined results of 3–6
independent experiments with normalization to vector-transduced cells
within each experiment.
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dependently contribute to T cell cytopathicity. Furthermore,
they suggest that CD4 binding efficiency or CXCR4 binding
efficiency alone is not solely responsible for cytopathicity, as
mapping data for each of these sensitivities do not correlate
directly with cytopathicity.
The V5-gp41 region, not the V1/V2 region, contributes to
enhanced replication and pathogenesis of the R3A Env in
the thymus
Based on the in vitro studies, we suspected that either V1/
V2 or V5-gp41 would contribute to replication and patho-
genesis of the R3A Env in the thymus organ. In contrast, the
pre-V1 region, including Vpr, Vpu, Tat, Rev, and part of Env,
and the V4 regions did not show a contribution in any in vitro
assay and were therefore less likely to play a role.
Accordingly, we tested the V1/V2 and V5-gp41 chimeric
Env proteins in the context of recombinant NL4-3 viruses for
replication and pathogenesis in HF-TOC.
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p24 ELISA of HF-TOC supernatant. Consistent with
previous findings, NL4-R3A replicated to higher levels
than either NL4-3 or NL4-R3B, a difference most notable at
the earliest time point (Fig. 8A). Surprisingly, in spite of the
clear contribution of the V1/V2 region to viral entry, CD4
binding efficiency, and cytopathicity in vitro, recombinants
with a switch in the V1/V2 region showed an identical
replication phenotype as their parental envelope. In contrast,
swapping the V5-gp41 region resulted in an intermediate
phenotype, with greater replication than NL4-R3B and less
replication than NL4-R3A for both NL4-R3A (R3B V5-
gp41) and NL4-R3B (R3A V5-gp41).
Depletion of CD4+ thymocytes directly correlated with
viral replication. While NL4-R3B was able to cause some
depletion of CD4+ thymocytes, NL4-R3A caused almost
complete depletion by 11–12 dpi (Fig. 8B). V1/V2
swapping between the Env proteins caused no change in
this phenotype, consistent with the lack of change in viral
replication. In contrast, switching V5-gp41 resulted in an
intermediate phenotype, with NL4-R3B (R3AV5-gp41) andFig. 8. V5-gp41, but not V1/V2, of the R3A Env is uniquely involved in HIV r
viruses expressing the indicated Env were used to infect thymus fragments in the H
supernatant at the indicated times post-infection. Shown are the combined data from
total CD4+ thymocytes using FACS. Shown are the combined results from five ind
to both NL4-R3B and NL4-R3A at days 11–12 ( P < 0.05).NL4-R3A (R3B V5-gp41) both causing significantly less
depletion than NL4-R3A and significantly more depletion
than NL4-R3B. We conclude that the V5-gp41 region of
R3A is partially, but not completely, responsible for the
increased replication and cytopathicity of the R3A and the
NL4-R3A viruses, whereas the V1/V2 region makes no
contribution. Notably, the Env recombinants with high
pathogenic activity in the thymus possessed either the
R3A V5-gp41 region or increased CXCR4 binding effi-
ciency, and full pathogenic activity of the R3A Env appears
to require both determinants.Discussion
The ways in which HIV-1 Env contributes to the
pathogenesis of AIDS remain to be fully elucidated. In this
study, we utilize the human fetal-thymus organ culture to
assess the mechanisms of pathogenesis of a primary,
transmitted Env associated with rapid disease progression.
The R3A and R3B Env proteins, derived from the sameeplication and pathogenesis in the thymus model. (A) NL4-3 recombinant
F-TOC system. Replication was monitored by detection of p24 in the TOC
five independent infections. (B) Pathogenesis was assessed by depletion of
ependent experiments. *Indicates significant differences in depletion relative
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replicate similarly in stimulated PBMCs, yet behave very
differently in the context of the thymic microenvironment
(Meissner et al., 2004). We show that the R3A Env excels in
a number of contexts in vitro, including viral entry, binding
efficiency for CD4 and CXCR4, and fusion-induced
cytopathicity. Coreceptor affinity (Etemad-Moghadam et
al., 2000; Karlsson et al., 1998; Si et al., 2004), syncytium-
inducing ability (Etemad-Moghadam et al., 2000; Karlsson
et al., 1998), entry (Chakrabarti et al., 2002; Si et al., 2004),
and fusogenicity (Chakrabarti et al., 2002; Etemad-Mogha-
dam et al., 2000, 2001; Karlsson et al., 1998) have all been
previously correlated with envelope-mediated pathogenesis
in vivo and thus were not wholly unexpected. Most
significantly, we find that enhanced CD4 binding efficiency,
associated with enhanced viral entry and cytopathicity in
vitro, makes no contribution to replication and pathogenesis
in the thymus organ.
It has been widely observed that tissue-culture-adapted
isolates evolve enhanced affinity for CD4 upon passage in
vitro (Daar and Ho, 1991; Hoxie et al., 1991; Kozak et al.,
1997; Platt et al., 1997), likely because association of virus
with CD4 is the rate limiting step for viral infectivity in in
vitro systems (Kabat et al., 1994). Consistent with these
findings, soluble CD4 sensitivity of each chimeric envelope
(Fig. 6B) was directly proportional to viral entry of T cells in
vitro (Fig. 6A). Analysis of chimeric envelopes in these
assays revealed the clear contribution of the V1/V2 region
to both CD4 binding efficiency and viral entry. Furthermore,
the V1/V2 region was partially responsible for fusion-
induced cytopathicity in the Sup-T1 cell line (Fig. 7). These
findings are consistent with the observation that loss of a
glycosylation site in V1/V2 of a primary isolate passaged in
vivo results in enhanced affinity for CD4 (Pugach et al.,
2004). In spite of these V1/V2 contributions in vitro, R3B
(R3A V1/V2) and R3A (R3B V1/V2) are indistinguishable
from their parental envelope in the thymus (Fig. 8). Thus,
the V1/V2 region has no effect on replication and patho-
genesis in a representative lymphoid microenvironment.
These data raise the intriguing possibility that viral patho-
genesis in vivo is not dependent on the efficiency of
interaction of envelope with the CD4 receptor, even though
CD4 binding is a prerequisite for viral infection. The lack of
studies reporting a difference in CD4 binding efficiency of
isolates during disease progression or in simian studies of
pathogenesis is consistent with this notion (Cayabyab et al.,
1999; Chakrabarti et al., 2002; Ivey-Hoyle et al., 1991;
Karlsson et al., 1998; Si et al., 2004). Notably, simian
studies conclude CD4 binding efficiency is unimportant
because pathogenic SHIV Env proteins have the same or
lower CD4 affinity than non-pathogenic SHIV Env proteins
(Cayabyab et al., 1999; Chakrabarti et al., 2002; Karlsson et
al., 1998; Si et al., 2004). Our study is the first to show
directly that enhanced CD4 binding efficiency does not
contribute to replication and pathogenesis in a human
lymphoid organ. That enhanced viral entry in vitro is notrelevant for pathogenesis in vivo has support from at least
one simian model (Hsu et al., 2003). Rather, it is likely that
modulation of CD4 binding efficiency is associated with
avoidance of a neutralizing antibody response and immune
recognition (Pugach et al., 2004). Minor differences in CD4
binding efficiency among isolates would then merely be a
byproduct of this variation (Ivey-Hoyle et al., 1991).
Instead, post-CD4 binding events are likely to modulate
viral replication and pathogenesis in vivo. While CCR5
binding efficiency and T20 sensitivity were not found to
differ between R3A and R3B in vitro, the R3A Env did
show enhanced CXCR4 binding efficiency and fusion-
induced cytopathicity in T cells (Fig. 3). While we were
unable to map CXCR4 binding efficiency to one particular
region (Fig. 6C), the V5-gp41 region clearly contributed to
syncytium-induced cytopathicity in vitro (Fig. 7). Our
genetic data suggest that increased binding efficiency for
CXCR4 and the V5-gp41 region may be independently and
additively responsible for R3A Env pathogenesis in the
thymus. Thus, while the R3A (R3B V5-gp41) Env main-
tains high binding efficiency for CXCR4, it loses the R3A
V5-gp41 region and yields a partially pathogenic envelope
in the thymus (Fig. 8). Similarly, the R3B (R3A V5-gp41)
Env maintains low CXCR4 binding efficiency, but gains the
R3A V5-gp41 determinant, also yielding a partially patho-
genic envelope in the thymus. Only when both CXCR4
binding efficiency and the R3A V5-gp41 region are
maintained on one Env (NL4-R3A and NL4-R3A (R3B
V1/V2)) is full thymic pathogenesis observed. These results
are consistent with previous monkey studies implicating
coreceptor binding efficiency and the gp41 region, through
as yet unclear mechanisms, to viral pathogenesis (Etemad-
Moghadam et al., 2000, 2001; Karlsson et al., 1998). To our
knowledge, this is the first support of these conclusions
determined experimentally in a human model for HIV-1.
Further study will be required to elucidate the potential
mechanisms by which coreceptor binding efficiency and the
V5-gp41 region modulate viral pathogenesis and to more
definitively identify the responsible regions.
Our finding that CXCR4 binding efficiency is correlated
with thymic pathogenesis is representative of a number of
recent studies that have correlated coreceptor binding
efficiency with viral pathogenesis (de Parseval et al., 2004;
Etemad-Moghadam et al., 2000; Gorry et al., 2002; Karlsson
et al., 1998, 2004) and disease progression (Stalmeijer et al.,
2004). Enhanced interaction with CXCR4 could presumably
overcome SDF1a-mediated inhibition (Scarlatti et al., 1997)
or low CXCR4 expression on certain target cells (Berkowitz
et al., 1998; Tokunaga et al., 2001; Zaitseva et al., 1998).
Alternatively, this interaction may result in stronger signal
transduction which could alter the activation status and/or
susceptibility of thymocytes to viral infection or depletion
(Arthos et al., 2002; Hernandez-Lopez et al., 2002; Holm et
al., 2004; Pedroza-Martins et al., 1998). Additionally,
because both R3B and R3A are capable of using CXCR4,
the nature of interaction with coreceptor could impact
E.G. Meissner et al. / Virology 336 (2005) 184–197 193infection, particularly because inclusion of AMD-3100 was
able to almost completely block replication and pathogenesis
of both NL4-R3A and NL4-R3B in the thymus (data not
shown). In support of this hypothesis, while HXB2 and the in
vivo-evolved LW isolate both only use CXCR4 as a
coreceptor, only the LW Env is permissive for infection in
the thymus (Miller et al., 2001; Su et al., 1997), demonstrat-
ing that the nature of the Env–CXCR4 interaction may affect
viral replication and pathogenesis in vivo.
It is unclear how R3A Env is able to achieve enhanced
binding efficiency for CXCR4. No one region is either
necessary or sufficient to increase or abrogate CXCR4
binding efficiency (Fig. 6C). Because this is commonly
observed in studies of chimeric Env proteins with CXCR4
(Cho et al., 1998; de Vreese et al., 1996; Singh and
Collman, 2000; Smyth et al., 1998), coreceptor binding
efficiency is likely to be a complex phenotype mediated by
specific evolution within diverse regions of each individual
Env. Interestingly, while V3 has typically been associated
with coreceptor binding efficiency and usage (Etemad-
Moghadam et al., 2000; Foda et al., 2001; Hu et al., 2000;
Ogert et al., 2001; Si et al., 2004; Su et al., 1997), R3B and
R3A have identical V3 loops making a direct contribution of
this region to the observed differences improbable. It is
possible that the nature of the R3A Env–CXCR4 interaction
is conformationally distinct, as has previously been
described for other Env proteins (Brelot et al., 1999;
Karlsson et al., 2004; Labrosse et al., 2001; Picard et al.,
1997), such that Env binding is less sensitive to AMD-3100
inhibition.
The conclusions from our study are limited by the broad
regions included in each chimeric Env, particularly the lack
of separation between the V5 and gp41 regions. Further
separation of pathogenic motifs will help elucidate the exact
mechanisms of R3A pathogenesis in the human thymus. In
this study, which relies on genetic correlation, we conclude
that enhanced CXCR4 binding efficiency and the V5-gp41
region of Env appear to independently contribute to patho-
genesis of the R3A Env in the thymus. In contrast, elevated
V1/V2-mediated fusion, CD4 binding efficiency, and
cytopathicity of R3A do not contribute to thymic patho-
genesis. These data suggest that in vitro assessment of
CXCR4 binding efficiency and cytopathic potential, as well
as replication and pathogenesis in the human thymus, may
approximate the pathogenic potential of HIV-1 in vivo. The
R3A and R3B Env proteins and their derivatives will be
valuable in further understanding the pathogenic activity of
HIV-1 Env in the thymus and in disease progression.Materials and methods
Viral isolates and cell lines
pNL4-3 was used to construct the recombinant viruses
NL4-R3A, NL4-R3B, and each chimeric NL4-R3A/R3Bconstruct as previously described using EcoR1 and Xho1
restriction sites (Meissner et al., 2004). A293T and TZM-bl
cells (NIAID, NIH) were cultured in DMEM with 10%
FBS. GHOST-CXCR4 cells (NIAID, NIH) were cultured in
DMEM supplemented with 10% FBS, 500 Ag/ml G418,
100 Ag/ml hygromycin, and 1 Ag/ml puromycin. U373-
MAGI-CXCR4CEM and U373-MAGI-CCR5E cells
(NIAID, NIH) were cultured in DMEM supplemented with
10% FBS, 0.2 mg/ml G418, 0.1 mg/ml hygromycin B, and
1.0 Ag/ml puromycin. Sup-T1 (NIAID, NIH) and 1G5 cells
(NIAID, NIH) were cultured in RPMI 1640 with 10% FBS.
Chimeric envelope construction
Chimeric R3A/R3B Envs were created using conserved
restriction sites. EcoR1 and DraIII sites were used to create
the pre-V1 chimeras which include a switch of the vpr, vpu,
rev, tat, and the env gene from amino acids 1–123
including the C1 region and are designated as pre-V1.
DraIII and Acc1 were used to create chimeras between
amino acids 124 and 319, including regions V1, V2, C2,
and part of V3, and are designated as the V1/V2 region.
Acc1 and BsaB1 were used to create chimeras from amino
acids 320–440 including part of V3, C3, V4, and part of
C4, and are designated as the V4 region. BsaB1 and Xho1
were used to create chimeras from amino acids 441–853
including part of C4, V5, C5, and gp41, and are designated
as the V5-gp41 region.
Monoclonal antibodies and drugs
The 2G12 monoclonal antibody (NIAID, NIH) was used
for cell surface envelope staining. AMD-3100 (NIAID,
NIH) was reconstituted in water at a stock concentration of
802 AM. TAK-779 (NIAID, NIH) was reconstituted in
DMSO per protocol at a stock concentration of 2 mM. T20
was obtained from Dr. S. Jiang (New York Blood Center,
NY) and was reconstituted at a stock concentration of
0.5 mg/ml in 50% ethanol. Recombinant soluble human
CD4 was obtained from Progenics Pharmaceuticals. The
Leu-3a antibody was obtained from Becton Dickinson.
Antiserum to HIV-1SF2 gp120 (NIAID, NIH) and the p24
hybridoma (183-H12-5C) (NIAID, NIH) were used to
assess envelope incorporation into virions.
Viral production
VSVg-pseudotyped retrovirus was produced by calcium-
phosphate cotransfection of A293T cells with VSVg, Gag/
Pol, and MSCV retroviral DNA as previously described
(Coffield et al., 2003, 2004; Pear et al., 1993). The MSCV
retroviral construct contains GFP under control of the
phospho-glucose kinase promoter and envelope under
control of the CMV promoter (after transfection) or the
MSCV LTR (after transduction). Virus in DMEM (2% FBS)
was harvested 2 and 3 days post-transfection, clarified by
E.G. Meissner et al. / Virology 336 (2005) 184–197194low speed centrifugation, aliquoted, and stored at  80 -C.
NL4-luciferase pseudotyped with HIV-1 Env was produced
by calcium-phosphate cotransfection of A293T cells with
NL4-luciferase and an MSCV retroviral construct encoding
env, and was harvested and stored as above. To produce
infectious NL4-3, NL4-R3A, and the other chimeric viruses,
proviral DNA was transfected into A293T cells using
Effectene (Qiagen) and the supernatant was used to infect
PHA-stimulated PBMCs as previously described (Meissner
et al., 2004). Virus was harvested from 4 to 9 days post-
infection and tittered using U373-MAGI-CXCR4CEM or
TZM-bl cells.
shRNA construction and X4 KD cells
We designed our hairpin oligo based on the Shagging
protocol developed by Dr. Hannon’s group at Cold Spring
Harbor Laboratories (Hannon, 2004): X4h oligo: 5V-
AAAAAAGTTATCCGAAGTATACATACTAATCCCCT-
CAAGCTTCAGGGGATCAGTATATACACTTCAGA-
TAACGGTGTTTCGTCCTTTCCACAA-3V. The oligo was
used for PCR to splice the shRNA targeting hCXCR4 onto
the hU6 promoter. The PCR product was gel purified and
ligated into the PCR2.1 cloning vector (Invitrogen). The
cloned product was digested from PCR2.1 using SpeI/XbaI
and subsequently cloned into the XbaI site located within
the 3VLTR of our MSCV retroviral vector, thus creating a
SIN vector. The correct clone was confirmed using the
HindIII site incorporated into the loop region of the hairpin
oligo. This construct was used to transduce Sup-T1 cells,
resulting in ¨97% reduction of surface CXCR4 levels
without affecting CD4 expression.
Entry assays
For the virus-cell fusion assay, A293T cells were co-
transfected using Effectene (Qiagen) with proviral DNA and
a Blam-vpr expression construct (pMM310) as previously
described (Cavrois et al., 2002; Lineberger et al., 2002).
Virus was harvested in phenol red-free DMEM (10% FBS,
10 mM HEPES), clarified by centrifugation, aliquoted, and
stored at  80 -C. The amount of virus in each stock was
determined by p24 ELISA. 1  105 Sup-T1 cells were
infected in 96-well plates in a total volume of 150 Al phenol-
free DMEM (10% FBS, 10 mM HEPES). Infection was
achieved by spinoculation at 2000  g for 2 h at 22 -C
followed by a 2-h incubation at 37 -C (O’Doherty et al.,
2000). After centrifugation and supernatant removal, cells
were resuspended in 100 Al HBSS and 20 Al 6  loading
dye (GeneBlazer In vivo Detection Kit, 1 AM CCF2-AM,
Invitrogen), covered from light, and incubated at 22 -C.
After 1 h, the dye solution was aspirated after centrifugation
and cells were washed 1  in PBS. Cells were resuspended
in 100 Al PBS and transferred to a clear-bottomed 96-well
plate (Costar 3603). After 8–16 h, fluorescence was
measured on a fluorometer and relative fusion wasdetermined by taking the ratio of the blue (cleaved) to
green (uncleaved) signal after background correction as
previously described (Cavrois et al., 2002).
T cell cytopathicity assays
5  105 Sup-T1 or 1G5 cells were infected by
spinoculation with 500 Al RPMI 1640 (10% FBS), 500 Al
of VSVg-pseudotyped retrovirus, and 8 Ag/ml polybrene.
Cells were incubated at 22 -C for 30 min and then
centrifuged at 2000  g for 2–3 h (22 -C). Transduced
cells were cultured in 0.5 ml RPMI 1640 (10% FBS) in a
12-well plate. 2–3 days post-transduction, cells were
counted by trypan blue exclusion with blinding of sample
identity. Transduction efficiency was monitored by FACS
analysis of GFP expression. To detect surface levels of
envelope, 5  104 cells were stained with 10 Ag/ml 2G12
anti-gp120 monoclonal antibody or an isotype control
followed by secondary staining with goat F(ab’)2 antihuman
IgG (Fc Sp.)-PE (Caltag).
Inhibition of infection
Cell lines and dosage of drug for each particular
experiment are indicated in Results. For Tak-779, AMD-
3100, and Leu-3a studies, target cells were preincubated
with drug for 1 h at 37 -C prior to infection. For sCD4
inhibition studies, virus was preincubated with sCD4 for 2 h
at 37 -C prior to addition to target cells. For all studies,
relative inhibition was determined by comparing the amount
of infection in the presence of each concentration of drug to
the amount of infection without drug for each virus.
Human fetal-thymus organ culture
The procedure for HF-TOC has been previously
described (Bonyhadi et al., 1995; Meissner et al., 2004;
Miller et al., 2001). Briefly, human fetal thymuses (19–24
gestational weeks) were dissected into ¨2-mm3 fragments
using a dissecting microscope. 5–6 fragments were placed
on organotypic culture membranes (Millipore) underlaid by
media (RPMI with 10% fetal bovine serum, 50 Ag of
streptomycin/ml, 50 U of penicillin G/ml, 1  MEM
vitamin solution (Gibco/BRL), 1  insulin-transferrin-
sodium selenite medium supplement (Sigma), and beta-
mercaptoethanol) in 6-well tissue culture plates. An equal
amount of virus (100–800 IU) in 15 Al of supernatant from
infected PHA-stimulated PBMCs or mock supernatant was
applied to each fragment. Viral and mock supernatants
produced from the same PBMC donor were used within
each experiment. Fragments were cultured at 37 -C in 5%
CO2 for 10–12 days with daily changes of culture media.
Thymocytes were teased out of the fragments using pestles
(Bellco Co.) and were stained with CD4-PE and CD8-TC
(Caltag) in PBS–2% fetal bovine serum, washed, and
resuspended in PBS–1% formaldehyde for FACS analysis.
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percentage of cells that stained positive for CD4, including
CD4+CD8+ and CD4+CD8 thymocytes. To measure viral
replication, HF-TOC supernatant prepared in PBS–1%
Triton X-100 was measured using an Alliance p24 ELISA
kit (Perkin-Elmer).
Statistics
Student’s t test was used for statistical analysis in each
experiment. P values of less than 0.05 were considered to
be statistically significant. In cases where data from
multiple experiments were combined, P values were
determined using the averages from each independent
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